Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Extension Study of UCB0599 in Parkinson's Disease
NCT05543252Phase 2Terminated
- Sponsor
- UCB
- Start
- Aug 2022
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 2 trial of minzasolmin in Parkinson's disease (PD), sponsored by UCB. Started Aug 2022; status: terminated.
02
Drugs
minzasolmin
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT05543252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05543252.